Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders
May 11 2020 - 08:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, with an initial focus on
myelodysplastic syndromes (MDS), today announced that, as disclosed
in the Company’s Definitive Proxy Statement for the Company’s 2020
Annual Meeting of Stockholders, due to the public health impact of
the COVID-19 pandemic, the Company’s Annual Meeting of Stockholders
will be held in a virtual meeting webcast format, beginning
at 10:30 a.m. EDT on Wednesday, May 27, 2020.
Stockholders will not be able to attend the Annual Meeting in
person.
Onconova stockholders as of the close of
business on March 30, 2020 can join the live virtual
meeting. Stockholders will be able to listen, vote and submit
questions from any remote location with internet connectivity.
Instructions on how to participate in the Annual Meeting and
demonstrate proof of stock ownership are on your proxy card and
will be posted in advance of the Annual Meeting at
www.virtualshareholdermeeting.com/ONTX2020. If you have any
questions or need assistance voting, please contact our proxy
solicitor MacKenzie Partners, Inc. at proxy@mackenziepartners.com
or 800-322-2885.
Whether or not stockholders plan to attend the
Annual Meeting, they are urged to vote and submit their proxy card
in advance of the meeting by one of the methods described in the
proxy materials for the Annual Meeting.
THE COMPANY’S 2020 PROXY STATEMENT CONTAINS
IMPORTANT INFORMATION AND THIS ANNOUNCEMENT SHOULD BE READ IN
CONJUNCTION WITH THE 2020 PROXY STATEMENT. THE 2020 PROXY STATEMENT
AND OTHER RELEVANT MATERIALS ARE AVAILABLE FOR FREE AT THE U.S.
SECURITY & EXCHANGE COMMISSION’S WEBSITE (www.sec.gov) AND AT
THE COMPANY’S WEBSITE (www.onconova.com).
About Onconova Therapeutics,
Inc.
Onconova Therapeutics, Inc. is a Phase 3-stage
biopharmaceutical company focused on discovering and developing
novel drugs to treat cancer, with an initial focus on
myelodysplastic syndromes (MDS). Onconova has a pipeline of
proprietary targeted agents designed to work against specific
cellular pathways that are important in cancer cells. Advanced
clinical trials with the Company’s lead compound, rigosertib, are
aimed at what the Company believes are unmet medical needs of
patients with MDS. Onconova has conducted trials with two other
research compounds and has a pre-clinical program with a CDK4/6 and
ARK5 inhibitor, ON 123300.
For more information, please visit
https://www.onconova.com/.
Forward-Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, and involve risks and uncertainties.
These statements relate to Onconova expectations regarding the
INSPIRE Trial and Onconova’s other development plans. Onconova has
attempted to identify forward-looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes. Although Onconova believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including Onconova's ability to continue as a going
concern, maintain its Nasdaq listing, the need for additional
financing, the success and timing of Onconova's clinical trials and
regulatory approval of protocols, our collaborations including the
effective termination of the HanX license and securities purchase
agreements and plans for partnering certain territories, and those
discussed under the heading "Risk Factors" in Onconova's most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q. Any forward-looking statements contained in this release
speak only as of its date. Onconova undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Press release contact
information
Company Contact:Avi Oler
Onconova Therapeutics, Inc. 267-759-3680
ir@onconova.us
http://www.onconova.com/contact/
MediaDavid Schull, Russo Partners
LLC: (212) 845-4271Nic Johnson, Russo Partners LLC: (212)
845-4242
InvestorsJan Medina, CFA, Russo Partners LLC:
(646) 942-5632
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2023 to Mar 2024